188 related articles for article (PubMed ID: 38200586)
1. Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population.
Dell'Aquila K; Vadlamani A; Maldjian T; Fineberg S; Eligulashvili A; Chung J; Adam R; Hodges L; Hou W; Makower D; Duong TQ
Breast Cancer Res; 2024 Jan; 26(1):7. PubMed ID: 38200586
[TBL] [Abstract][Full Text] [Related]
2. Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features.
Meti N; Saednia K; Lagree A; Tabbarah S; Mohebpour M; Kiss A; Lu FI; Slodkowska E; Gandhi S; Jerzak KJ; Fleshner L; Law E; Sadeghi-Naini A; Tran WT
JCO Clin Cancer Inform; 2021 Jan; 5():66-80. PubMed ID: 33439725
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
4. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Warner ET; Ballman KV; Strand C; Boughey JC; Buzdar AU; Carey LA; Sikov WM; Partridge AH
Breast Cancer Res Treat; 2016 Aug; 159(1):109-18. PubMed ID: 27449492
[TBL] [Abstract][Full Text] [Related]
5. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
6. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer.
Bitencourt AGV; Gibbs P; Rossi Saccarelli C; Daimiel I; Lo Gullo R; Fox MJ; Thakur S; Pinker K; Morris EA; Morrow M; Jochelson MS
EBioMedicine; 2020 Nov; 61():103042. PubMed ID: 33039708
[TBL] [Abstract][Full Text] [Related]
7. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
[TBL] [Abstract][Full Text] [Related]
8. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
Zhu Q; Tannenbaum S; Kurtzman SH; DeFusco P; Ricci A; Vavadi H; Zhou F; Xu C; Merkulov A; Hegde P; Kane M; Wang L; Sabbath K
Breast Cancer Res; 2018 Jun; 20(1):56. PubMed ID: 29898762
[TBL] [Abstract][Full Text] [Related]
9. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
13. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
14. Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
Sarma M; Perimbeti S; Nasir S; Attwood K; Kapoor A; O'Connor T; Early A; Levine EG; Takabe K; Kalinski P; Ambrosone C; Khoury T; Yao S; Gandhi S
Breast Cancer Res Treat; 2022 Apr; 192(2):411-421. PubMed ID: 35000093
[TBL] [Abstract][Full Text] [Related]
15. Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy.
Liu HQ; Lin SY; Song YD; Mai SY; Yang YD; Chen K; Wu Z; Zhao HY
Eur Radiol; 2023 Apr; 33(4):2965-2974. PubMed ID: 36418622
[TBL] [Abstract][Full Text] [Related]
16. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
Kim JY; Jeon E; Kwon S; Jung H; Joo S; Park Y; Lee SK; Lee JE; Nam SJ; Cho EY; Park YH; Ahn JS; Im YH
Breast Cancer Res Treat; 2021 Oct; 189(3):747-757. PubMed ID: 34224056
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
Arasu VA; Kim P; Li W; Strand F; McHargue C; Harnish R; Newitt DC; Jones EF; Glymour MM; Kornak J; Esserman LJ; Hylton NM;
J Breast Imaging; 2020 Aug; 2(4):352-360. PubMed ID: 32803155
[TBL] [Abstract][Full Text] [Related]
20. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US.
Shubeck S; Zhao F; Howard FM; Olopade OI; Huo D
JAMA Netw Open; 2023 Mar; 6(3):e235834. PubMed ID: 36995711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]